Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b study of MIW815 (ADU-S100) plus PDR001 in advanced/metastatic solid tumors and lymphomas
jRCT2080223739Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 1, open-label trial of ADU-S100 in Nonhematologic neoplasms, lymphoma, melanoma and 2 more (2 cohorts), sponsored by Novartis. Started Dec 2017; status: completed.
02
Drugs
ADU-S100
03
Conditions
Nonhematologic neoplasmslymphomamelanomahead and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2080223739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223739.